Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×

Maintenance Message

Cambridge Core ecommerce is unavailable Sunday 08/12/2024 from 08:00 – 18:00 (GMT). This is due to site maintenance. We apologise for any inconvenience.

  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • Chapter 17 - Apolipoprotein E, hormone therapy, and neuroprotection

  • from Section 4 - Possible genetic factors related to hormone treatment effects
  • Edited by Eef Hogervorst, Loughborough University, Victor W. Henderson, Stanford University, California, Robert B. Gibbs, University of Pittsburgh, Roberta Diaz Brinton, University of Southern California
  • Book:
    Hormones, Cognition and Dementia
    Published online:
    06 July 2010
    Print publication:
    24 September 2009, pp 162-170

  • Summary

    Editors' introduction

    Struble and McAsey propose that apolipoprotein E (APOE) is a pivotal required intermediary in the neuroprotective effects of hormone replacement therapy (HT) not only in dementia but in other chronic neurological diseases. Basic science analyses indicate that 17β-estradiol increases APOE expression, which facilitates neuronal plasticity, neural repair, and could delay progression of several types of neurodegenerative disease. The issue of the APOE4 isoform, which may be a negative regulator of HT outcomes, is considered along with therapeutic implications for either increasing or decreasing its expression. These authors propose that subsequent studies of the impact of HT or selective estrogen receptor modulators on neurological function should include APOE genotyping.